Good efficacy achieved by baricitinib in the treatment of anti-MDA5 antibody-positive dermatomyositis with alopecia areata

Rheumatology (Oxford). 2022 Aug 3;61(8):e221-e223. doi: 10.1093/rheumatology/keac084.
No abstract available

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Alopecia Areata* / complications
  • Alopecia Areata* / drug therapy
  • Autoantibodies
  • Azetidines
  • Dermatomyositis* / complications
  • Dermatomyositis* / drug therapy
  • Humans
  • Interferon-Induced Helicase, IFIH1
  • Purines
  • Pyrazoles
  • Sulfonamides

Substances

  • Autoantibodies
  • Azetidines
  • Purines
  • Pyrazoles
  • Sulfonamides
  • Interferon-Induced Helicase, IFIH1
  • baricitinib

Supplementary concepts

  • Diffuse alopecia